Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines

Table 1 Current FDA approved GBCAs

Contrast agent	Trade name	Manufacture	Label dose	Age	FDA Approved indication
Gadopentetate Dimeglumine (Gd-DTPA2)	Magnevist^®	Bayer Healthcare	0.1 mmol/Kg (0.2 mL/Kg)	2 years and older	Central Nervous System* Extracranial/Extraspinal Tissues Body (excluding the heart)*
Gadodiamide (Gd-DTPA-BMA)	Omniscan^®	GE Healthcare	0.1 mmol/Kg (0.2 mL/Kg) 0.05 mmol/Kg (0.1 mL/Kg)§	2-16 years and adults	Central Nervous System* Body [noncardiac]****
Gadoversetamide (Gd-DTPA-BMEA)	OptiMark^®	Mallinckrodt	0.1 mmol/Kg (0.2 mL/Kg)	18 to 76 years	Central Nervous System* Liver
Gadoteridol	ProHance^®	Bracco Diagnostics	0.1 mmol/Kg (0.2 mL/Kg) Additional dose of 0.2 mmol/Kg (0.4 mL/Kg) §§§	2 - 18 years and adults	Central Nervous System* Extracranial/Extraspinal Tissues**
Gadobenate Dimeglumine (Gd-BOPTA)	MultiHance^®	Bracco Diagnostics	0.1 mmol/Kg (0.2 mL/Kg)	2 years and older	Central Nervous System*
Gadobutrol (Gd-DO3A-butrol)	Gadavist^® Gadovist^®;§§	Bayer Healthcare	0.1 mmol/Kg (0.1 mL/Kg)	2 years and older	Disrupted Blood Brain Barrier Central Nervous System*
Gadofosveset trisodium	Ablavar^® Vasovist^®§§	Lantheus Medcl	0.03 mmol/Kg (0.12 mL/Kg)	Adults	Aortoiliac occlusive disease
Gadoxetate disodium	Eovist^® Primovist^®§§	Bayer Healthcare	0.025 mmol/Kg (0.1 mL/Kg)	Adults	Liver Lesions
Outside the US only, shown for completeness
Gadoterate Meglumine (Gd-HP-DOTA)	Dotarem ^® Artirem ^® §§	Guerbet	0.1 mmol/Kg (0.2 mL/Kg)	2 years and older	Central Nervous System* Body [noncardiac]****

Other agents previously approved but not currently available are Mangafodipir Trisodium (Teslascan^®; GE Healthcare) and Ferumoxides (Feridex^®; Amag Pharms). NDA, New Drug Application. * Abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. ** Abnormal vascularity in the head and neck. *** Abnormal vascularity in the body. **** Intrathoracic, abdominal, pelvic cavities, and the retroperitoneal space. § For Kidney studies. §§ Only for use outside the United States. §§§ May be given up to 30 minutes after the first dose for patients with normal renal function suspected of having poorly enhancing central Nervous System lesions.

ISSN: 1532-429X